-
SCG Cell Therapy Announces FDA IND Clearance of SCG142, a next-generation HPV-specific TCR T cell therapy for patients with HPV-associated solid tumor
SINGAPORE, July 1, 2024 --(PRNewswire)-- SCG Cell Therapy Pte Ltd (SCG), a biotechnology company developing novel immunotherapies for infectious diseases and their associated cancers, today announced that U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application to initiate Phase 1/2 clinical trial for SCG142
2024-07-01
-
Clinical Data of First-in class HBV-specifcTCRT Cell Therapy (SCG101)Presented atESAL Congress ShowingImproved OverallSurvival in HBV-relatedHepatocellularCarcinoma
SINGAPORE, 7 June 2024 – SCG Cell Therapy Pte Ltd (SCG), a clinical-stage biotechnology company developing novel immunotherapies for infectious diseases and their associated cancers, announced that clinical data from its first-in-class autologous hepatitis B virus (HBV)-specific T-cell receptor-engineered T Cell (TCR T) therapy – SCG101 – was featured in a late-breaking session during the European Association for the Study of the Liver (EASL) Congress 2024 in Milan, Italy.
2024-06-07
-
SCG Presented Preclinical Data in an Oral Presentation at ASGCT 2024 Highlighting Superior Tumor Inhibition of its Immunoswitch Armored HPV-TCR T Cell Therapy (SCG142) against HPV-associated Cancers
SINGAPORE, 13 May 2024 – SCG Cell Therapy Pte Ltd (SCG), a clinical-stage biotechnology company developing novel immunotherapies for infectious diseases and their associated cancers, announced first preclinical data of its novel human papillomavirus (HPV)-specific T cell receptor-engineered T (TCR T) cell therapy armored with an TGFβRII-41BB immunoswitch – SCG142 – in an oral presentation at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting in Baltimore, Maryland.
2024-05-13
-
SCG CELL THERAPY AND A*STAR LAUNCH JOINT LABS WITH COLLABORATION NEARING S$30 MILLION TO ADVANCE iPSC TECHNOLOGY TOWARDS SCALABLE GMP MANUFACTURING OF CELLULAR IMMUNOTHERAPIES
Collaboration aims to develop scalable GMP-grade iPSC manufacturing processes and therapeutic candidates to facilitate research leading to translation of novel cellular immunotherapies.
2024-04-17
-
Significantly Reduce Manufacturing Cost and Increased Local Production: SCG Cell Therapy Opens State-of-the-art Cell Therapy Manufacturing Facility and R&D Centre in Singapore
星汉德生物隆重宣布全球生产研发中心在新加坡落成启动,该中心推出首创全新封闭式自动化细胞治疗生产系统,率先实现“新加坡制造业2030愿景
2023-07-21
-
成功突破乙肝功能性治愈的根本性障碍,星汉德生物全球首创双特异性抗体荣获 EASL最佳报告奖
2023-07-12